Previous 10 | Next 10 |
Shares of Celldex Therapeutics (NASDAQ: CLDX) were jumping 10.8% higher as of 3:10 p.m. EDT on Tuesday. This marked the second day of big gains for the stock. Celldex's shares skyrocketed on Monday on the company's positive results from a phase 1b study evaluating CDX-0159 in tr...
MediaCo (MDIA) +312%.State Auto Financial (STFC) +191%.SGOCO (SGOC) +104%.SCWorx (WORX) +59%.Tempest (TPST) +54%.Origin Agritech (SEED) +41%.Datasea (DTSS) +39%.Creatd (CRTD) +33%.Cemtrex (CETX) +32%.Ayala Pharmaceuticals (AYLA) +29%.Celldex Therapeutics (CLDX) +25%.Baosheng Media (BAOS) +25%...
Celldex reported positive results from the phase 1b study using CDX-0159 for the treatment of patients with Chronic Inducible Urticaria; Complete response rate of 95%. Expansion opportunity for CDX-0159 exists in that results from a phase 1 study using this drug to treat patients with...
Do You Have These Top Health Care Stocks On Your Watchlist Right Now? With countries across the globe combating the coronavirus pandemic, health care stocks are still in the limelight. After all, this section of the stock market today is home to companies focused on this nob...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Celldex Therapeutics, Inc. Shares Surge After Positive Trial Data ” Celldex Therapeutics, Inc. (NASDAQ: CLDX) climbed over 31% in premarket trading aft...
Celldex Therapeutics (CLDX) announces that it is proposing to sell $175M of shares in an underwritten public offering.Expects to grant the underwriters a 30-day option to purchase up to an additional $26.25M of shares.Intends to use the net proceeds to continue clinical and preclinical develo...
Shares of Celldex Therapeutics (NASDAQ: CLDX) were skyrocketing 28.4% as of 10:47 a.m. EDT on Monday. The big jump came after the company announced positive data from its ongoing phase 1b clinical study evaluating CDX-0159 in treating two of the most common types of hives. With ...
Penny Stocks Don’t Always Stay Low-Priced Forever; Here Are Some That Made A Splash This Year When it comes to penny stocks , the average person is likely trading them. Why would anyone want to invest in penny stocks? They’re high-risk, extremely volatile, and usually ...
Mario13/E+ via Getty Images IDEXX downgraded Heska, Covetrus upgraded at Guggenheim With its mid-year rating changes, Guggenheim makes no adjustments to its positive views on animal health space. However, noting the bullish prospects in diagnostics, the analysts have upgraded Heska (HSKA) and...
Vertigo3d/E+ via Getty Images Richard Branson made it into space. Beating Amazon's (AMZN) Jeff Bezos, who is scheduled to make his flight later this month, Virgin Galatic (SPCE) launched a fully crewed spaceflight over the weekend, including its billionaire founder Branson onboard. Disney (DI...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...